MedPath

A Comparative Study of 3-point With 1-point Mesh Fixation in TAPP for Gilbert Type III Inguinal Hernia

Not Applicable
Completed
Conditions
Chronic Pain
Seroma
Recurrence
Infections
Hernia, Inguinal
Hematoma
Registration Number
NCT05929378
Lead Sponsor
Nanchong Central Hospital
Brief Summary

This study was designed to compare the outcome of 3 point with 1 point lightweight mesh fixation in TAPP surgery for patients with type Ⅲ gilbert inguinal hernia. The main outcome include seroma, chronic pain, recurrence, et al.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
351
Inclusion Criteria

Unilateral indirect inguinal hernia according to preoperative physical examination and imaging examination.

The inclusion criteria were as follows: primary indirect inguinal hernia classified as Gilbert III (defect size diameter ≥3cm, including scrotal hernias)

Exclusion Criteria

Age below 18 years or older than 80. Direct hernia, femoral hernia, recurrent hernia, incarcerated hernia, strangulated hernia, and other types of hernias.

Patients not suitable for general anesthesia. Patients requiring open surgery; patients requiring emergency surgery Loss to follow-up or communication difficulties, or poor compliance.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
recurrence6 months

Check for recurrence by clinical examination or ultrasound at 6 months postoperatively

Postoperative pain6 months

The visual analog scale (VAS) was adopted for pain evaluation 2 days, 3 months, and 6 months postoperatively. The scale range from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain.

Secondary Outcome Measures
NameTimeMethod
postoperative complications6 months

Including infection, seroma, hematoma

Trial Locations

Locations (1)

Yunhong Tian

🇨🇳

Nanchong, Sichuan, China

Yunhong Tian
🇨🇳Nanchong, Sichuan, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.